lnu.sePublikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Palbociclib can overcome mutations in cyclin dependent kinase 6 that break hydrogen bonds between the drug and the protein
Federal University of São Carlos, Brazil.
National Center for Tumor Diseases (NCT), Germany;German Cancer Research Center (DKFZ) Heidelberg, Germany.
Federal University of São Carlos, Brazil.
Federal University of São Carlos, Brazil.
Visa övriga samt affilieringar
2017 (Engelska)Ingår i: Protein Science, ISSN 0961-8368, E-ISSN 1469-896X, Vol. 26, nr 4, s. 870-879Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Inhibition of cyclin dependent kinases (CDKs) 4 and 6 prevent cells from entering the synthesis phase of the cell cycle. CDK4 and 6 are therefore important drug targets in various cancers. The selective CDK4/6 inhibitor palbociclib is approved for the treatment of breast cancer and has shown activity in a cellular model of mixed lineage leukaemia (MLL)-rearranged acute myeloid leukaemia (AML). We studied the interactions of palbociclib and CDK6 using molecular dynamics simulations. Analysis of the simulations suggested several interactions that stabilized the drug in its binding site and that were not observed in the crystal structure of the protein-drug complex. These included a hydrogen bond to His 100 that was hitherto not reported and several hydrophobic contacts. Evolutionary-based bioinformatic analysis was used to suggest two mutants, D163G and H100L that would potentially yield drug resistance, as they lead to loss of important protein-drug interactions without hindering the viability of the protein. One of the mutants involved a change in the glycine of the well-conserved DFG motif of the kinase. Interestingly, CDK6-dependent human AML cells stably expressing either mutant retained sensitivity to palbociclib, indicating that the protein-drug interactions are not affected by these. Furthermore, the cells were proliferative in the absence of palbociclib, indicating that the Asp to Gly mutation in the DFG motif did not interfere with the catalytic activity of the protein.

Ort, förlag, år, upplaga, sidor
Wiley-Blackwell, 2017. Vol. 26, nr 4, s. 870-879
Nyckelord [en]
resistance mutations, molecular dynamics, protein-drug interactions, DFG motif
Nationell ämneskategori
Biokemi och molekylärbiologi
Forskningsämne
Kemi, Biokemi
Identifikatorer
URN: urn:nbn:se:lnu:diva-64193DOI: 10.1002/pro.3135ISI: 000398183800020Scopus ID: 2-s2.0-85014629748OAI: oai:DiVA.org:lnu-64193DiVA, id: diva2:1097918
Tillgänglig från: 2017-05-23 Skapad: 2017-05-23 Senast uppdaterad: 2019-08-29Bibliografiskt granskad

Open Access i DiVA

Fulltext saknas i DiVA

Övriga länkar

Förlagets fulltextScopus

Personposter BETA

Friedman, Ran

Sök vidare i DiVA

Av författaren/redaktören
Friedman, Ran
Av organisationen
Institutionen för kemi och biomedicin (KOB)
I samma tidskrift
Protein Science
Biokemi och molekylärbiologi

Sök vidare utanför DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetricpoäng

doi
urn-nbn
Totalt: 144 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf